Press Release Archives • Fragile X Research

Positive Results Reported in Phase II Fragile X Clinical Trial of PDE4D Inhibitor from Tetra Therapeutics

FRAXA Research Foundation Berry-Kravis, Elizabeth • Gurney Mark • Has Results • Press Release • Research Updates November 2, 2020December 21, 2020Alzheimer's, amyloid precursor protein, autism, BPN14770, drug tolerance, FDA, mGluR, mGluR5, NIH, PDE4, TAT (Trans-Activator of Transcription), Tetra Therapeutics

Today, Tetra Therapeutics announces the first unequivocally positive phase 2 clinical trial in Fragile X syndrome, press release below. The results do not depend on carving out a subset of patients or post hoc analysis.

FRAXA Biotech Games™ Reimagined as Online Event for 2020

FRAXA Research Foundation Press Release June 9, 2020June 11, 2020Alzheimer's, autism, iPS

FRAXA Biotech Games™, a gathering of Boston area biotech companies to network in a friendly setting, and form new relationships and potential collaborations while raising money for Fragile X research, is adapting its 2020 event to maintain its commitment to Fragile X and autism research while prioritizing the health and safety of its contestants and volunteers. The organization’s traditional annual event will be transformed into an online interactive experience September 9-11, 2020.

20 Landmarks Will Light Up for Fragile X Awareness Day

FRAXA Research Foundation Press Release July 15, 2019July 17, 2019amyloid precursor protein, autism, TAT (Trans-Activator of Transcription)

Newburyport, MA (July 15, 2019) — Today, FRAXA Research Foundation announces that 20 buildings, bridges and landmarks across the United States and Canada will be illuminated teal on Monday, July 22, to celebrate International Fragile X Awareness Day. The goal of the initiative is to raise awareness of Fragile X syndrome, the most common inherited cause of autism and learning disabilities worldwide.